adxs

adxs is the NASDAQ ticker symbol used to represent Advaxis, Inc., a United States biotechnology company known for developing cancer immunotherapies based on Listeria monocytogenes vectors. The company’s core approach uses attenuated Listeria bacteria to deliver tumor-associated antigens to antigen-presenting cells, with the aim of stimulating a T-cell–mediated immune response against cancer cells.

Advaxis’s lead product candidate was AXAL (axalimogene filolisbac), a live-attenuated Listeria vaccine designed to target HPV-associated cancers by expressing the HPV-16 E7 antigen. AXAL underwent clinical testing in cervical cancer and other HPV-related malignancies, with studies reporting immunogenicity and signals of clinical activity, though no regulatory approvals had been granted.

The pipeline included additional Listeria-based vaccine candidates for various cancers, developed or evaluated in preclinical or early clinical settings. The company also pursued partnerships and licensing arrangements to advance its platform and to secure capital for ongoing research and development.

Advaxis faced the financial and regulatory challenges common to small biotechs, including funding pressures, clinical trial setbacks, and fluctuations in stock trading. These factors affected its market presence and corporate status over time, with shares trading in more volatile segments of the market. As with many early-stage biotechnology programs, the trajectory of adxs depended on successive trial results, regulatory milestones, and access to capital; current status and future prospects depended on ongoing disclosures by the company and its investors.